Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul;55(7):e70017.
doi: 10.1002/eji.70017.

Platelet-Based Nanotechnology Improves Cancer Immunotherapy

Yanlin Lv  1 , Guanghui Ma  1   2
Affiliations
Review

Platelet-Based Nanotechnology Improves Cancer Immunotherapy

Yanlin Lv et al. Eur J Immunol. 2025 Jul.

Abstract

Cancer immunotherapy is a cornerstone of precision medicine, yet its efficacy is often hampered by the immunosuppressive and heterogeneous microenvironment of solid tumors. Biomimetic nanodelivery systems have emerged as promising tools to enhance therapeutic outcomes while minimizing off-target effects. Among these, platelet (PLT)-based systems offer unique advantages, including prolonged circulation, immune evasion, and tumor-targeting capabilities. Of particular value is their ability to localize to sites of injury, which is a feature that nanocarriers cannot achieve. This review explores the multifaceted role of platelets in tumor development and metastasis, highlighting their bidirectional interactions with tumors. It further discusses the application of PLT-based nanotechnology in cancer immunotherapy, emphasizing recent advancements in immune regulation, targeted therapy, and clinical translation. We also address the challenges and considerations in developing PLT-based platforms, outlining future directions for their optimization in cancer treatment.

Keywords: cancer immunotherapy; nanodelivery systems; platelet.

PubMed Disclaimer

References

    1. J. D. Twomey and B. L. Zhang, “Cancer Immunotherapy Update: FDA‐Approved Checkpoint Inhibitors and Companion Diagnostics,” The AAPS Journal [Electronic Resource] 23, no. 2 (2021): 39.
    1. S. Agrawal, E. Park, and P. G. Kluetz, “FDA Approvals in 2024: New Options for Patients Across Cancer Types and Therapeutic Classes,” Nature reviews Clinical Oncology 22 (2025): 457–458.
    1. P. C. Zhang, Y. H. Zhai, Y. Cai, Y. L. Zhao, and Y. P. Li, “Nanomedicine‐Based Immunotherapy for the Treatment of Cancer Mestastasis,” Advanced Materials 31 (2019): 1904156.
    1. J. Li, H. M. Zeng, L. W. Li, Q. Yang, L. He, and M. Q. Dong, “Advanced Generation Therapeutics: Biomimetic Nanodelivery System for Tumor Immunotherapy,” ACS Nano 17, no. 24 (2023): 24593–24618.
    1. S. Y. Zuo, J. X. Song, J. X. Zhang, Z. G. He, B. J. Sun, and J. Sun, “Nano‐immunotherapy for each Stage of Cancer Cellular Immunity: Which, Why, and What?,” Theranostics 11, no. 15 (2021): 7471–7487.

LinkOut - more resources